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Hepatitis C virus remains a large health care burden to the world. Incidence rates across the world fluctuate and are 
difficult to calculate given the asymptomatic, often latent nature of the disease prior to clinical presentation. Prevalence 
rates across the world have changed as well with more countries aware of transfusion-related hepatitis C and more and 
more evidence supporting intravenous drug use as the leading risk factor of spread of the virus. This article reviews 
current hepatitis C virus prevalence and genotype data and examines the different risk factors associated with the virus.  
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1.  Prevalence 
Hepatitis C virus (HCV) continues to be a major 
disease burden on the world. In 1999, the WHO 
estimated a worldwide prevalence of about 3% with the 
virus affecting 170 million people worldwide. [1] (Table 
1). Generally, most studies of prevalence use blood 
donors to report the frequency of HCV usually by anti-
HCV antibodies and do not report follow-up HCV 
testing. Using blood donors as a prevalence source may 
underestimate the real prevalence of the virus because 
donors are generally a highly selected population. [2]  
In the Third National Health and Nutrition 
Examination Survey (NHANESIII) from 1988 to 1994, an 
estimated HCV prevalence of 3.9 million people was 
found in the United States (US) with 2.7 million people 
found to have chronic infection with HCV (positive HCV 
RNA). Neither sex nor racial-ethnic group was found to 
be independently correlated with HCV infection. 
However, a majority of patients that were HCV positive 
were below the age of 50. [2]  
Among Central and South America, a recent 
community based study in San Juan, Peurto Rico, 
showed that estimated prevalence of HCV in 2001-2002 
was 6.3%. [3]  In Mexico, the prevalence reported was 
about 1.2%. (4) Among blood donors in Chile and Brazil, 
prevalence of HCV Ab was low - 0.3%, 1.14% 
respectively. [5,32]  
In Europe, general prevalence of HCV is about 1% 
but varies among the different countries. [6] Prevalence 
of HCV antibody is 0.87% (1993-1994) in Belgium. [7] In 
the United Kingdom, at least 200,000 adults carry HCV. 
[8] In Northern Italy, prevalence of HCV Ab was 3.2%. 
[9] Three studies in Central and Southern Italy showed a 
higher rate of HCV (8.4%-22.4%), especially in the older 
population. [10-12] Among patients of general 
practitioners in Lyon, France, the prevalence of HCV was 
estimated to be 1.3%, very similar to the French general 
population. [13] Within the Russian army, frequency of 
anti-HCV was 1.5% among servicemen and donors with 
increased prevalence in the North Caucasus, Far East 
and Siberia (3.1-3.8%) compared to the Transbaikal 
region (0.7%). [14] Low rates were found in Hungary 
(0.73% of 15,864 blood donors.) [31] 
Table 1: Hepatitis C estimated prevalence and number infected 
by WHO Region. Source: Weekly Epidemiological Record. N° 
49, 10 December 1999, WHO. 
WHO Region  Total 
Population 
(Millions) 
Hepatitis C 
prevalence 
Rate % 
Infected 
Population 
(Millions) 
Number-of 
countries by 
WHO Region 
where data are 
not available 
Africa 602 5.3 31.9  12 
Americas 785  1.7  13.1  7 
Eastern 
Mediterranean 
  
466 
4.6 21.3  7 
Europe 858 1.03 8.9  19 
South-East Asia  1 500  2.15  32.3  3 
Western Pacific  1 600  3.9  62.2  11 
Total 5  811  3.1 169.7  57 
 
Recently, HCV prevalence studies have come out of 
Pakistan in the Middle East. 751 out of 16,400 patients 
(4.57%) were found to +HCV Ab from 1998-2002 with the 
largest age group from 41-50. [15] Among male blood 
donors in Karachi, Pakistan, the seroprevalence of HCV 
was 1.8% with a trend of increasing proportion of 
positive donors from 1998-2002. [16] There has been very 
high prevalence rates of HCV reported in Egypt in the 
past (28%). [17] This was confirmed among 90 blood 
donors in Cairo, where 14.4% were anti-HCV positive by 
RIBA test. [18] Then 26.6% among 188 blood donors and 
22% among 163 donors were positive with both studies 
done in Cairo. [19, 20] Rates were lower in Saudi Arabia 
(1.8%) and Yemen (2.1%). [33, 34] 
Intermediate rates of HCV have been reported out 
of Asia. From 1995-2000, 0.49% anti-HCV Ab were 
detected among 3,485,648 blood donors in Japan. [44] 
This was lower than the 0.98% our of 10,905,489 blood 
donors reported in 1992. [21] In China, prevalence rates 
were generally low with rates around 1% among donors 
in Beijing and Wuhan. [22, 23] However, rates may be 
higher in certain areas such as the Hubei province 
(30.13%) and Inner Mongolia Autonomous Region 
(31.86%). [24] Low rates have been found in Malaysia 
(around 1.6%) and Singapore (0.54%). [25.26] Higher 
rates of HCV have been found in Thailand (3.2-5.6%). 
[27, 28] Within a smaller community of 103 residents in 
Sherpas, Nepal, only 1 person had a borderline reaction Int. J. Med. Sci. 2006, 3  42
in 2004. [29] In New Delhi, India, 1.85% of blood donors 
were positive. [30]  
There have been fewer studies out of Africa, but 
lower rates have been reported – 1.6% among blood 
donors in Ethiopia and 0.9% in Kenya. [35, 36]   
The estimated prevalence in Australia has been 
recently reported as 2.3% with the virus affecting 210,000 
people by 2001. The 20-24 year old age group had the 
highest prevalence with strong majority of the infected 
population below the age of 50. [37]   
2.  Risk Factors 
Intravenous drug use 
Transmission of Hepatitis C virus has been strongly 
associated with intravenous and percutaneous drug and 
needle use.   Reported cases of hepatitis C from 
intravenous drug use is on the rise in the US.  In a study 
of injection drug users in Baltimore, Maryland from 1988 
to 1996, 30.3% of participants developed anti-HCV 
antibodies with most in the first 2 years of the study. [38] 
Among 310 drug users in Antwerp and Limburg in 
Belgium, 71% and 46% had anti-HCV antibody, 
respectively. [39] The Hepatitis C European Network for 
C-operative Research (HENCORE) group reported a 
prevalence of hepatitis C of 80% among intravenous 
drug users (IVDU). [6] In the District Buner study in 
Pakistan, all 751 anti-HCV patients had a history of 
injections. [15] 90% of IVDU in Chang Rai, Thailand were 
positive for HCV. [27] 36.6% of randomly selected IVDU 
in Sydney, Australia and 74% of IVDU in Melbourne, 
Australia were HCV positive. [42,43] A recent study in 
London, England took 428 intravenous drug users below 
the age of 30 and found that 44% had antibodies to 
hepatitis C compared to 4% with HIV. This came out to 
an incidence of 41.8 cases per 100 person years of 
antibody to HCV. [40]   
The importance of intravenous drug use can not be 
overemphasized. The prevalence of HCV among people 
who acquired HIV through intravenous drug use reaches 
90%. [41] Co-infection of the two viruses can make 
treatment all the more difficult. Most countries with a 
young population of HCV infection must deal with 
intravenous drug use as the leading cause for spread of 
the virus. Many of these intravenous drug users do not 
know they are infected. Screening of HCV and treatment 
of substance abuse are extremely important in this 
group.  
Blood Transfusions 
Transfusion of blood products has been a leading 
cause of transmission of H C V ;  h o w e v e r ,  d u e  t o  
improved screening, transmission through transfusions 
has decreased in most developed countries. In Japan, 
incidence of post-transfusion non-A non-B hepatitis 
among those with less than 10 transfusions dropped 
from 4.9% (1988-Oct ‘89) to 1.9% (Nov’89-90) after 
screening with first-generation anti-HCV test was 
introduced. [45] In the US, incidence of post-transfusion 
hepatitis C dropped from 3.84% to 0.57% per patient 
(0.03% per unit blood) after HCV screening was 
introduced in 1990. [46] In England, the frequency HCV 
infected donations dropped from 1 in 520,000 (1993-98) 
to 1 in 30 million (1999-2001) when donations were tested 
for HCV RNA. [47]  
However, incidence of transfusion related hepatitis 
C is still higher in other areas of the world. In a study of 
147 Chilean patients with chronic hepatitis C, the most 
common risk factor was blood transfusion in 54% versus 
just 5% with IVDU. [48] A study was done in the largest 
blood bank in Santa Catarina, Brazil from 1991-2001 
showing a significant drop in risk of acquiring HCV, but 
the lowest risk of 1:13721 was still almost 10 times higher 
than that of developed countries. [49] Despite better 
screening for selecting blood donors, there remains a 
need for some kind of HCV screening laboratory test.  
Sexual activity 
The role of sexual activity in the transmission of 
HCV remains unclear. In the NHANESIII study, number 
of sexual partners (OR 2.54 for 2-49 partners) and age at 
first sexual intercourse (OR 2.94) had significant 
correlation with HCV Ab and this has been confirmed in 
other studies. [2,3] Among 1257 non-IVDU in Baltimore 
at a STD clinic 9.7% were positive for HCV. [50] One 
hypothesis is that many of the hepatitis C patients may 
have injecting sexual partners. In one study, 15% of non 
IVDU women with an injecting partner had HCV. [51] 
More recently, a 10-year prospective follow-up study 
(8060 person-years) showed no evidence of sexual 
transmission among monogamous couples in Italy. [52] 
However, in a study among spouses in Egypt, it was 
estimated that wife to husband transmission was 34% 
and 10% among women with and without detectable 
HCV RNA. Husband to wife transmission was estimated 
at 3%. Overall, 6% were estimated to have contracted 
HCV from their spouse. [53] One most remember 
however that the prevalence of HCV is much higher in 
Egypt and this study did not emphasize monogamous 
relationships and transmission between spouses can only 
be assumed to be sexual in nature. Also recently, there 
was lack of evidence found for sexual transmission of 
HCV among men who have sex with men in the 
prospective ongoing Omega Cohort Study in the US 
(2653 person-years of follow-up). [54] All of this new 
evidence supports that sexual transmission of HCV is 
still rare but for some reason is higher among those with 
high-risk sexual activity.  
Hemodialysis 
It has been well documented that dialysis patients 
have a higher rate of HCV infection. In the 90’s much of 
the world reported anti-HCV prevalence rates of 10-50% 
among hemodialysis patients with lower rates in such 
places as Ireland (1.7%). [55-60] Previously, rates in 
Europe were as high as 20-30%. [6] A more recent report 
from Saudi Arabia showed a prevalence rate of HCV 
among hemodialysis patients to be 9.24% compared to 
0.30% among blood donors. [61] In a tertiary-care 
hospital in Mexico City, Mexico, the rate of anti-HCV 
was 6.7% compared to the roughly 1.2% prevalence in 
the population of Mexico. [62] The rate of seroconversion 
among hemodialysis patients with no other risk factors 
has been reported 1.38-1.9%/year. [63,64] These studies 
generally conclude that the transmission of the virus to 
hemodialysis patients is generally nosocomial with 
possible risk factors being failure to disinfect devices 
between patients, sharing of single-use vials for 
infusions, poor sterile technique, poor cleaning of 
dialysis machines, and poor distance between chairs. [65]  Int. J. Med. Sci. 2006, 3  43
Special Populations 
The prevalence of HCV has been noted to be higher 
in other populations as well. Among kidney transplants, 
the prevalence was reported to be as high as 33.3% in 
Italy with the frequency higher prior to 1990(50%) than 
after 1990 (27%). [66] Obviously, most of these kidney 
transplant patients underwent dialysis as well.  
The United States Veteran Affairs medical centers 
have also reported a higher prevalence of HCV than the 
general population with percentages as high as 35% in 
the VA Palo Alto system. [67] The most recent study 
among 20 centers reported an estimated prevalence of 
5.4% with 78% reporting a risk factor of either 
transfusion or intravenous drug use. Seropositivity was 
also associated with tattoo use and incarceration in this 
study. [68]  
There is also an increased prevalence of HCV also 
among prison inmates. One example is the Riverside 
county jail system where 25% adults incarcerated carried 
the virus while only 2% of the juvenile detention 
population carried HCV. [69] The juvenile detention 
population therefore provides a target for teaching and 
intervention since many of these juveniles acquire the 
virus early in their adult years.  
3.  Genotypes of HCV 
HCV is divided among six genotypes with 
numerous subtypes. These genotypes can differ up to 
30% from each other in nucleotide sequence. Depending 
on the HCV genotype, length of treatment can differ. 
G e n o t y p e  1 b  i s  l e s s  r e s p o n s i v e  t o  a l p h a - i n t e r f e r o n  
therapy compared to genotypes 2 and 3. It is therefore 
important to track the different genotypes of the HCV 
virus. In the NHANESIII study done in the US, 56.7% 
were classified as 1a, 17% as 1b, 3.5% as 2a, 11.4% as 2b, 
7.4% as 3a, 0.9% as 4, 3.2% as type 6. [2] 50% of all 
infections were by genotype 1 with a higher percentage 
of genotype 3 among the IVDU population in England. 
[70,71] Genotype 1b was the predominant genotype (46% 
among blood donors) in Chile and was found in all 
infected patients with hepatocarcinoma in one study. [5] 
This same genotype was also found in 82% of 147 chronic 
hepatitis C patients in Chile as well. [48] Genotype 1b is 
also dominant in Japan. [72-74] In Beijing, China, of 63 
HCV-RNA samples, 52% were genotype 2 and 29% type 
3. [22] In Thailand, HCV 3a was the most common 
genotype at 50-60% with 1a, 1b, and 6 comprising the 
rest (10-20% each). [27] Out of 90 patients in Estonia, 
73.3% carried 1b, 20% with 3a, and 6.7% with 2a. [75] 
Genotype 3 is most common on the Indian subcontinent 
while genotype 4 is the most common genotype in Africa 
and the Middle East. [76-80] Genotype 5 can be found in 
South Africa and as mentioned above, genotype 6 can be 
found in south-east Asia. [81,82]  
4.  Prevention 
Primary prevention of hepatitis C should target 
reduction of transmission of the virus. Prevention should 
target those at risk of acquiring the virus and should 
involve providing education, risk reduction counseling, 
HCV screening and substance abuse treatment. In the 
US, the Centers for Disease Control (CDC) suggest 
screening for the follow population: 
•  Persons who ever injected illegal drugs, including those 
who injected once or a few times many years ago.  
•  Persons who received a blood transfusion or organ 
transplant before July 1992.  
•  Persons who received clotting factor concentrates before 
1987.  
•  Persons who were ever on long-term dialysis.  
•  Children born to HCV-positive women.  
•  Healthcare, emergency medical, and public safety workers 
after needlesticks, sharps, or mucosal exposures to HCV-
positive blood.  
•  Persons with evidence of chronic liver disease.  
Extra attention should be given to populations in 
specific settings such as correctional institutions, drug 
treatment programs, programs for high risk youth, HIV 
counseling and testing sites, and STD clinics. In these 
settings, physicians should always screen for intravenous 
drug use. Unlike HIV, HCV is found in high 
concentrations in filters, spoons, and rinsing liquids that 
may be used in association with needle drug use. 
Patients should be counseled on contaminated 
equipment being a source of infection. Addiction care 
and counseling should be focused on with possible 
referrals for psychotherapy and detoxification. [83-85] 
Prevention in healthcare setting should also take 
place by having better sterilization, safer injections, 
reducing opportunities for percutaneous exposures to 
blood. In developing countries, better screening for 
donors and blood screening should take place to reduce 
the number of transfusion related transmissions.  
Once a patient is found to have hepatitis C, that 
patient needs to be counseled to reduce the risk of HCV 
transmission to others.  The physician should also offer 
counseling on treatment, reducing alcohol usage and 
immunization with hepatitis A, hepatitis B, 
pneumococcal and influenza vaccines. HCV negative 
persons with ongoing risk factors also require counseling 
and immunization with hepatitis A and hepatitis B 
vaccines. [83-85] 
Future research in this field will need to be 
continued. We will need to continue to evaluate the 
incidence of the virus third world countries as well as the 
transmissibility of the various genotypes.  Better 
prevention, screening and treatment methods for 
Hepatitis C virus all need to be elucidated.  
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